sodium 2-[(4R)-4-[(2S,5R,7R,10R,11S,15R)-5-hydroxy-2,15-dimethyl(4,4,5,6,6-2H5)tetracyclo[8.7.0.02,7.011,15]heptadecan-14-yl]pentanamido]ethane-1-sulfonate

• ChemBase编号: 178092
• 分子式: C26H44NNaO5S
• 平均质量: 505.68603
• 单一同位素质量: 505.28378879
• SMILES: C1[C@H](C[C@@H]2[C@](C1)(C1[C@@H](CC2)[C@H]2[C@](CC1)(C(CC2)[C@@H](CCC(=O)NCCS(=O)(=O)[O-])C)C)C)O.[Na+]
• Canonical SMILES: O[C@@H]1CC[C@]2([C@@H](C1)CC[C@@H]1C2CC[C@]2([C@H]1CCC2[C@@H](CCC(=O)NCCS(=O)(=O)[O-])C)C)C.[Na+]
• InChI: InChI=1S/C26H45NO5S.Na/c1-17(4-9-24(29)27-14-15-33(30,31)32)21-7-8-22-20-6-5-18-16-19(28)10-12-25(18,2)23(20)11-13-26(21,22)3;/h17-23,28H,4-16H2,1-3H3,(H,27,29)(H,30,31,32);/q;+1/p-1/t17-,18-,19-,20+,21?,22+,23?,25+,26-;/m1./s1
• InChIKey: YAERYJYXPRIDTO-XHYULEEXSA-M

名称和登记号

名称

• IUPAC标准名: sodium 2-[(4R)-4-[(2S,5R,7R,10R,11S,15R)-5-hydroxy-2,15-dimethyl(4,4,5,6,6-^2H₅)tetracyclo[8.7.0.0^2,^7.0^1^1,^1^5]heptadecan-14-yl]pentanamido]ethane-1-sulfonate
• IUPAC传统名: sodium 2-[(4R)-4-[(2S,5R,7R,10R,11S,15R)-5-hydroxy-2,15-dimethyl(4,4,5,6,6-^2H₅)tetracyclo[8.7.0.0^2,^7.0^1^1,^1^5]heptadecan-14-yl]pentanamido]ethanesulfonate
• 别名: 2-[[(3α,5β)-3-Hydroxy-24-oxocholan-24-yl-d5]amino]ethanesulfonic Acid Sodium Salt; N-(3α-Hydroxy-5β-cholan-24-oyl)taurine-d5 Monosodium Salt; NSC 681057-d5; Sodium Taurolithocholate-d5; Taurolithocholic Acid-d5 Sodium Salt

登记号

• CAS号: 1265476-97-8
• PubChem SID: 164234002
• PubChem CID: 46782976

理论计算性质

• Acid pKa: -0.8428335
• 质子受体: 5
• 质子供体: 2
• LogD (pH = 5.5): 1.0827354
• LogD (pH = 7.4): 1.0826962
• Log P: 2.192058
• 摩尔折射率: 127.9648 cm^3
• 极化性: 52.05299 Å^3
• 极化表面积: 106.53 Å^2
• 可自由旋转的化学键: 7
• 里宾斯基五规则: false

详细说明

Toronto Research Chemicals - T009102

The major human metabolite, a labelled bile acid which inhibits radioligand binding to muscarinic M1, but not to M2 or M3 receptors.

参考文献

• Javitt, N.B., et al.: J. Clin. Invest., 47, 1002 (1968)
• Bowmer, C., et al.: J. Pharm. Pharmacol., 37, 812 (1968)
• Ha, C., et al.: J. Biomed. Sci., 7, 114 (1968)
• Zaton, A., et al.: Chem. Biol. Interact., 124, 1 (1968)